India Pharma Outlook

India Pharma Outlook Pharma Outlook provides the industry experts analysis of the key pressures facing the Pharma Industry in the year ahead

Pharma Today: Pharma Sector’s Latest Financial PerformanceQ1 FY27 results highlight stronger financial performance acros...
21/08/2026

Pharma Today: Pharma Sector’s Latest Financial Performance

Q1 FY27 results highlight stronger financial performance across India’s pharma and healthcare sector, with Orchid Pharma, Manipal Hospitals and Mankind Pharma Limited posting major business developments.

Dilip Jose, Managing Director & CEO, Manipal Hospitals (MHEL), highlighted sustained patient demand and growth in high-acuity specialties. Atish Majumdar, Senior President, Sales and Marketing, Mankind Pharma, pointed to China’s biopharma innovation.

Novonesis and Novo Nordisk are advancing microbiome research alongside GLP-1 medicines. Together, these moves signal growth across chronic care, specialty therapies and strategic partnerships.

Read More: https://lnkd.in/dUR7b9fV

How Regulatory Readiness Can Shape Pharma's Global GrowthIn pharma, quality is no longer just about passing inspections....
20/08/2026

How Regulatory Readiness Can Shape Pharma's Global Growth

In pharma, quality is no longer just about passing inspections. It is about building a culture that protects patients, identifies risks before they escalate, and keeps global operations consistently ready.

In an interaction with Thiruamuthan, Assistant Editor at , Rashida Najmi, Chief Quality Officer, Piramal Pharma Limited, discusses the evolving quality and regulatory priorities shaping global pharmaceutical operations, with a focus on inspection readiness, patient safety, and sustainable growth.

With extensive experience across global quality and regulatory functions, Rashida has led compliance initiatives across India, the US, and Europe, strengthening quality systems and enabling regulatory approvals across diverse pharmaceutical operations.

Read More: https://lnkd.in/dZp5hsDE

Pharma Today: Oncology Enters a New Era of Precision Cancer CareThe next chapter of cancer care is taking shape through ...
20/08/2026

Pharma Today: Oncology Enters a New Era of Precision Cancer Care

The next chapter of cancer care is taking shape through personalized vaccines and AI-powered drug discovery.

Moderna, Inc. and Merck Group reported positive Phase 3 results for their mRNA melanoma vaccine, with CEO Stéphane Bancel calling the findings a “pivotal moment” for cancer research.

Meanwhile, Mayo Clinic and Sravathi Technologies are exploring a difficult pancreatic cancer target using AI. Parag Sharad Tipnis, CEO of Sravathi AI, said AI can fundamentally accelerate drug discovery and compress timelines that traditionally take years.

Together, these developments show how oncology research is combining immunotherapy, molecular targeting and AI to tackle difficult cancers.

Read More: https://lnkd.in/dm_DwbD6

Pharma Today: FDA Approvals Driving a New Phase for Indian PharmaFDA approvals are opening new growth opportunities for ...
19/08/2026

Pharma Today: FDA Approvals Driving a New Phase for Indian Pharma

FDA approvals are opening new growth opportunities for Indian pharma across regulated markets.

Lupin secured USFDA approval for Pitolisant Tablets, strengthening its US generic portfolio and CNS presence. Meanwhile, Johnson & Johnson received FDA 510(k) clearance for MONARCH QUEST 3, advancing AI-enabled robotic bronchoscopy.

Together, these developments highlight how regulatory milestones can strengthen market access, innovation and global expansion for pharma and healthcare companies.

Read More: https://lnkd.in/dJevpvAh

Pharma Today: AI Innovation, Drug Approvals & MoreFrom AI-powered drug development to breakthrough implants and new drug...
18/08/2026

Pharma Today: AI Innovation, Drug Approvals & More

From AI-powered drug development to breakthrough implants and new drug approvals, India’s pharma and healthcare landscape is moving into a faster, smarter and more innovation-driven phase.

Tata Consultancy Services advances drug development with agentic AI, with Debashis Ghosh highlighting its potential for scalable, audit-ready operations.

MANKIND PHARMA LTD releases its pledge on Bharat Serums and Vaccines Limited shares, while Biocon gains USFDA approval for Yesintek autoinjectors.

IIT Mandi develops safer 3D-printed bone implant coatings, and AIIMS New Delhi, with Roche India Healthcare Institute led by Rajji Mehdwan, launches a national retina training center.

Together, these developments highlight measurable progress across pharma innovation and healthcare capacity building.

Read More: https://lnkd.in/dfEiBsbk

Pharma Today: Drug Safety, Global Ambitions & MoreThe latest pharma updates spotlight drug safety, FDA compliance, clini...
17/08/2026

Pharma Today: Drug Safety, Global Ambitions & More

The latest pharma updates spotlight drug safety, FDA compliance, clinical practice and global ambitions.

Shilpa Medicare Limited recalled 27,923 chemotherapy vials, while Dr. Reddy's Laboratories Ltd.’s Laboratories received four FDA observations at its Hyderabad facility. Zydus Group manufactured the affected batches, while Amneal Pharmaceuticals handled US distribution.

The FDA recall highlights the importance of drug safety and quality controls for Indian pharma companies Dr Jitendra Singh urged clinically guided care, all while Congo’s Ebola outbreak updates turns out to be the deadliest.

Prime Minister Narendra Modi has called for stronger global representation for India’s pharmaceutical sector, urging Indian pharmaceutical companies to feature among the global top five.

In which SUN PHARMA Industries offers one example of the sector’s global expansion, with its Organon acquisition targeting $12.4 billion in revenue.

Read More: https://lnkd.in/dFh2QxZm

India’s Pharma Independence: Powering Aatmanirbhar Bharat in HealthcareIndia’s pharma independence has evolved from heav...
14/08/2026

India’s Pharma Independence: Powering Aatmanirbhar Bharat in Healthcare

India’s pharma independence has evolved from heavy import dependence in 1947 into a global manufacturing strength. Today, India ranks as the third-largest pharmaceutical producer by volume, supplies 20% of global generic medicines and contributes around 60% of global vaccine supplies.

Nikkhil K Masurkar, CEO, ENTOD Pharma, says India’s next phase should position the country as an “innovation partner and healthcare leader” for emerging economies.

Dr P. D. Vaghela, Secretary, Department of Pharmaceuticals, highlights how India’s COVID-19 response strengthened its reputation as the “Pharmacy of the World.”

With $30.5 billion in pharma exports in FY25, ₹4,763.34 crore invested under the Bulk Drugs PLI scheme and 55,100 tonnes of annual capacity established across 26 critical APIs and KSMs, India is building greater supply-chain resilience.

Bhanu Prakash Kalmath S J, Partner and Healthcare Industry Leader, Grant Thornton Bharat, points to the sector’s growing shift toward specialty portfolios and differentiated capabilities.

The next chapter will depend on biosimilars, complex generics, novel therapies, AI-driven R&D and drug discovery.

Together, these advances can take in healthcare beyond self-reliant manufacturing and toward innovation-led global leadership.

Read More: https://lnkd.in/dcw5mvk2

Fathima Noud, Correspondent,

Pharma Today: Drug Approvals, MedTech Innovation & MoreDrug approvals, MedTech innovation and pharma legal battles headl...
14/08/2026

Pharma Today: Drug Approvals, MedTech Innovation & More

Drug approvals, MedTech innovation and pharma legal battles headline today’s Pharma report as healthcare companies advance new therapies, technology partnerships and intellectual-property protection.

Bristol Myers Squibb secured FDA accelerated approval for Zenbexus (iberdomide) for relapsed or refractory multiple myeloma, priced at $29,500 per 28-day cycle.

Heartnet India partnered with IIT Jodhpur Technology Park to advance AI-powered healthcare, diagnostics and next-generation MedTech. Narayana Health and the New Development Bank (NDB) signed a pact focused on smart hospitals, digital health and technology transfer.

Novartis defended Entresto’s patent in the UK, retaining protection through 2028. Zydus Hospitals also strengthened its trademark position after the Delhi High Court upheld protection for its “Biochem” mark, registered since 1959.

Together, these developments show pharma’s growing focus on advanced treatments, technology-led healthcare and stronger intellectual-property protection.

Read More: https://lnkd.in/deejz9Ru

Why Vaccine Innovation Must Go Beyond Traditional PlatformsIn an exclusive interview with Thiruamuthan, Assistant Editor...
13/08/2026

Why Vaccine Innovation Must Go Beyond Traditional Platforms

In an exclusive interview with Thiruamuthan, Assistant Editor at , Dr. Rajan Sriraman, Research & Development Vaccines Head at Reliance Life Sciences, discusses the evolution of vaccine R&D, the role of recombinant technologies and advanced expression systems, regulatory readiness for emerging vaccine platforms, market-driven innovation, mucosal immunization, personalized vaccines, and the capabilities required to lead the next generation of vaccine development.

Read More: https://lnkd.in/dcw2sAac

Pharma Today: Pharma Exports, Drug Regulation & MorePharma exports, drug regulation and rare disease therapies headline ...
13/08/2026

Pharma Today: Pharma Exports, Drug Regulation & More

Pharma exports, drug regulation and rare disease therapies headline today’s Pharma Today report as India strengthens overseas shipments while regulators tighten quality controls.

Maharashtra FDA cancelled 10 Ayurvedic drug licenses, signaling tighter quality oversight. India’s pharma exports rose 6.8% to USD 8.10 billion in Q1 FY27, strengthening its global footprint.

Merck & Co. and GSK face a potential shift toward separate MMR vaccines. Zydus Hospitals’ Sentynl entered an alvelestat deal, with Sharvil Patel calling it a pivotal step for its rare disease strategy.

NephroPlus posted 23.7% revenue growth, as Vikram Vuppala highlighted India’s shift toward organized dialysis networks.

Together, these updates reflect a pharma industry balancing scale with quality, global expansion with regulatory scrutiny, and established products with new therapeutic opportunities.

Read More: https://lnkd.in/dQ2N5DY5

Address

Bangalore
560017

Website

Alerts

Be the first to know and let us send you an email when India Pharma Outlook posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to India Pharma Outlook:

Shortcuts

Share

Category